On 2016 Aug 29, CREBP Journal Club commented:

The three comparisons included in the Hope-3 trial show the effect of a) blood pressure lowering medication b) lipid lowering medication and c) the combination in patients who would traditionally be considered low risk (a risk over 5.6 years of approximately 5% or about 1% pa). The results are broadly consistent with previous trials of blood pressure and lipid lowering therapy, showing similar reduction in risk of cardiovascular events as a proportion of baseline risk. The non-significant results of the blood pressure lowering trial might be explained by either the hypothesis put forward by the study authors (greater effect in patients with higher baseline blood pressure) but could also be explained by the high proportion of patients using non-trial blood pressure lowering drugs at baseline and the difference in the number of patients using non-trial drugs between the active and the placebo arms of the trial. From the results of the lipid lowering arm of the trial, 1000 people would need to take the drug for 5.6 years to prevent 11 events. Whether this is worthwhile needs consideration at both a public and individual patient level.

On 2016 Aug 29, Jenny Doust commented:

None

On 2016 Aug 29, Jenny Doust commented:

None

On 2016 Aug 29, CREBP Journal Club commented:

The three comparisons included in the Hope-3 trial show the effect of a) blood pressure lowering medication b) lipid lowering medication and c) the combination in patients who would traditionally be considered low risk (a risk over 5.6 years of approximately 5% or about 1% pa). The results are broadly consistent with previous trials of blood pressure and lipid lowering therapy, showing similar reduction in risk of cardiovascular events as a proportion of baseline risk. The non-significant results of the blood pressure lowering trial might be explained by either the hypothesis put forward by the study authors (greater effect in patients with higher baseline blood pressure) but could also be explained by the high proportion of patients using non-trial blood pressure lowering drugs at baseline and the difference in the number of patients using non-trial drugs between the active and the placebo arms of the trial. From the results of the lipid lowering arm of the trial, 1000 people would need to take the drug for 5.6 years to prevent 11 events. Whether this is worthwhile needs consideration at both a public and individual patient level.